Australia’s medical technology sector is about to mint a new unicorn. Heidi Health, the Melbourne company whose software listens in on doctor and patient conversations and turns them into clinical notes, is on the cusp of a funding round that would value it at roughly $1 billion, according to reporting by the Australian Financial Review.
The milestone would cap an extraordinary two years for a business that barely registered on the national radar in 2023. Heidi builds what the industry calls an ambient clinical scribe: an AI assistant that sits quietly in the background of a consultation, transcribes what is said, and drafts the paperwork a clinician would otherwise type up by hand. The pitch is simple and, for time-poor doctors, deeply appealing. Less administration, more time with patients, and fewer nights spent finishing notes long after the last appointment.
From backer’s darling to billion-dollar valuation
Heidi’s rise has been underwritten in large part by Rick Baker and the team at Blackbird Ventures, the same firm that famously backed Canva in its earliest days. That pedigree matters, because Blackbird has said Heidi has been growing faster than any company in its portfolio, Canva included. For a fund whose reputation was built on spotting Melbourne and Sydney software companies before the rest of the market caught on, that is a striking claim, and it goes some way to explaining why investors are prepared to write cheques against a ten-figure valuation.
You can read the original AFR report on Heidi’s impending unicorn status, which frames the deal as one of the standout Australian technology stories of the year. Heidi was co-founded by Thomas Kelly, a doctor-turned-founder who has spoken often about the mountain of documentation that eats into a clinician’s day. The company has expanded well beyond Australia, with a large and growing base of users in the United States, where the appetite for tools that reduce clinician burnout is enormous.
The number that will draw headlines is the valuation, but the number that matters commercially is usage. Heidi has repeatedly pointed to millions of patient consultations processed through its platform, and it is that volume, rather than any single marquee contract, that has convinced backers the business has found genuine product-market fit. In a software category where many rivals are still chasing their first hospital deals, Heidi has been signing up individual clinicians, clinics and health networks at pace.
Two sides of the ambient AI boom
Not everyone is uniformly bullish, and the ambient scribe market is getting crowded fast. Heidi competes with well-funded American players such as Abridge and Nuance, the latter now owned by Microsoft, along with a swarm of smaller start-ups. Optimists argue that Heidi’s early lead, its clinician-first design and its Australian regulatory grounding give it a durable advantage. The counter-view, held by some investors who watch health tech closely, is that ambient documentation could become a commodity feature bundled into the big electronic medical record systems, squeezing margins for standalone providers over time.
There is also the question every AI company in medicine must answer: accuracy and trust. A scribe that mishears a dosage or drops a symptom from a note is not a productivity tool, it is a clinical risk. Heidi and its peers stress that a human clinician always reviews and signs off on the output, and that the software is an assistant rather than a decision-maker. Regulators here and overseas are still working out where ambient AI sits within existing medical device and privacy frameworks, and that uncertainty is one of the few clouds on an otherwise sunny outlook.
Why this matters for Australia
For the local technology scene, a Melbourne-headquartered medical AI unicorn is a genuinely significant moment. Australia has produced a handful of software giants, with Canva and Atlassian the obvious reference points, but comparatively few have emerged from health, an area where the country has world-class research but a patchy record of turning it into scaled commercial businesses. Heidi joining the unicorn club would be evidence that the AI wave is finally helping Australian founders build globally competitive companies in sectors beyond design and developer tools.
The story also lands at a moment when Australia’s health system is under acute workforce strain. General practices, emergency departments and regional clinics are all grappling with staff shortages and administrative overload, and any technology that hands clinicians back time has an obvious appeal to state health departments and private operators alike. If Heidi can demonstrate measurable reductions in documentation time without compromising safety, it becomes not just a start-up success story but a potential piece of the national productivity puzzle that policymakers keep talking about.
There is a sovereignty angle too. Much of the AI infrastructure Australian businesses rely on is built and hosted offshore, a point that has featured heavily in recent debates about local capability. A homegrown company handling sensitive clinical conversations, subject to Australian privacy law and built by Australian clinicians, offers a counterpoint to the idea that the country is destined to be a pure consumer of overseas AI.
What happens next
The immediate question is whether the funding round closes at the valuation being discussed, and which investors join the register. A billion-dollar mark would put pressure on Heidi to keep growing into that number, particularly in the fiercely contested US market where customer acquisition is expensive and competitors are deep-pocketed. Watch for how the company balances that international push against its Australian base, and whether it moves beyond documentation into adjacent tasks such as coding, billing and clinical decision support, where the real long-term margins may sit.
For now, though, the significance is hard to overstate. A company that most Australians have never heard of is about to become one of the country’s most valuable private technology businesses, built on the unglamorous but universal problem of medical paperwork. If it holds, Heidi’s ascent will be studied closely by every founder wondering whether the next Canva-scale story could come out of an examination room rather than a design studio.
Sources: Australian Financial Review, Technology.
